HIGHLIGHTS
- who: Yang Yang from the Washington in StLouis, United States have published the article: Toll-like receptor-targeted anti-tumor therapies: Advances and challenges, in the Journal: (JOURNAL)
- what: The authors report on the applications of TLR-targeted treatment in anticancer therapies in clinical trials, encompassing various combinatory therapeutic strategies. Four studies have since completed with published results. The trial showed moderate response to the vaccine among patients (40% developed antitumor CD8 T_cell response, associated with favorable clinical outcomes), good treatment efficacy (89% were minimal residual disease negative), and a good safety profile . This trial . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.